Annals of Laboratory Medicine

Korean Society for Laboratory Medicine (대한진단검사의학회)
권호 표지
DOI QR코드

DOI QR Code

Reclassification of Acute Myeloid Leukemia According to the 2022 World Health Organization Classification and the International Consensus Classification Using Open-Source Data

  • Jiwon Yun (Department of Laboratory Medicine, Korea University Anam Hospital, Korea University College of Medicine)
  • Received : 2024.04.18
  • Accepted : 2024.12.10
  • Published : 2025.03.01
Download PDF
⟨ Previous Next ⟩

Abstract

Background: In 2022, the revised WHO classification and International Consensus Classification (ICC) for myeloid neoplasms were published. We examined the impact of these guidelines on AML diagnoses alongside the 2022 European LeukemiaNet (ELN) recommendations on risk stratification. Methods: We included 450 adult patients with newly diagnosed AML (non-acute promyelocytic leukemia) from the cBioPortal open-source dataset. Diagnoses and risk stratifications were revised based on the new guidelines and compared with the 2017 WHO classification. Survival analyses were performed using Cox regression. Results: Among the patients included, 190 (42.2%) had consistent diagnoses across the three classifications, whereas 225 (50.0%) had inconsistent diagnoses. The two major WHO 2017 subtypes, AML not otherwise specified (AML-NOS) and AML with myelodysplasia-related changes (AML-MRC), were further subdivided according to the WHO 2022 and ICC. The ICC had the highest prognostication power among the three classifications. Subgroup analysis according to the different definitions of myelodysplasia-related AML and the introduction of AML with mutated TP53 (AML-TP53) showed that the differentiation of AML-TP53 was beneficial. The update from ELN 2017 to ELN 2022 resulted in significant transitions in a subset of patients. The updated diagnostic classification and ELN risk stratification (i.e., the ICC and ELN 2022) showed a straightforward relationship. Conclusions: This study presents an integrative comparative analysis of past and current guidelines for AML diagnosis and risk classification based on open-source data. The ICC diagnostic criteria are clinically significant for determining AML prognosis. In line with the changing treatment paradigm for AML, future research is needed to continuously validate diagnostic and risk stratification systems.

Keywords

Acknowledgement

This study was supported by the research fund of the Korean Association of External Quality Assessment Service (Grant No. KEQAS-2024-12).

References

  1. Jaffe ES, Harris NL, et al. eds. WHO classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. 3rd ed. Lyon (France): International Agency for Research on Cancer, 2001.
  2. Swerdlow SH, Campo E, et al. eds. WHO Classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon (France): International Agency for Research on Cancer, 2008.
  3. Swerdlow SH, Campo E, et al. eds. WHO Classification of tumours of haematopoietic and lymphoid tissues. Revised 4th ed. Lyon (France): International Agency for Research on Cancer, 2017.
  4. WHO Classification of Tumours Editorial Board. Haematolymphoid tumours. WHO classification of tumours series, 5th ed., volume 11. Lyon (France): International Agency for Research on Cancer, 2024.
  5. Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka HM, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 2022;140:1200–28. https://doi.org/10.1182/blood.2022015850
  6. Huber S, Baer C, Hutter S, Dicker F, Meggendorfer M, Pohlkamp C, et al. AML classification in the year 2023: how to avoid a Babylonian confusion of languages. Leukemia 2023;37:1413–20. https://doi.org/10.1038/s41375-023-01909-w
  7. Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115:453–74. https://doi.org/10.1182/blood-2009-07-235358
  8. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017;129:424–47. https://doi.org/10.1182/blood-2016-08-733196
  9. Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 2022;140:1345–77. https://doi.org/10.1182/blood.2022016867
  10. Sargas C, Ayala R, Larráyoz MJ, Chillón MC, Rodriguez-Arboli E, Bilbao C, et al. Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group. Blood Cancer J 2023;13:77. https://doi.org/10.1038/s41408-023-00835-5
  11. Lachowiez CA, Long N, Saultz J, Gandhi A, Newell LF, Hayes-Lattin B, et al. Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia. Blood Adv 2023;7:1899–909. https://doi.org/10.1182/bloodadvances.2022009010
  12. Lee C, Kim HN, Kwon JA, Yoon SY, Jeon MJ, Yu ES, et al. Implications of the 5th edition of the World Health Organization classification and International Consensus Classification of myeloid neoplasm in myelodysplastic syndrome with excess blasts and acute myeloid leukemia. Ann Lab Med 2023;43:503–7. https://doi.org/10.3343/alm.2023.43.5.503
  13. Bottomly D, Long N, Reister Schultz A, Kurtz SE, Tognon CE, Johnson K, et al. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. Cancer Cell 2022;40:850–64.e9. https://doi.org/10.1016/j.ccell.2022.07.002
  14. Wang X, Wang J, Wei S, Zhao J, Xin B, Li G, et al. The latest edition of WHO and ELN guidance and a new risk model for Chinese acute myeloid leukemia patients. Front Med (Lausanne) 2023;10:1165445. https://doi.org/10.3389/fmed.2023.1165445
  15. DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 2020;383:617–29. https://doi.org/10.1056/NEJMoa2012971